Abstract
Aims:
To evaluate whether the Asthma Control Test™ (ACT) score is predictive of Global Initiative for Asthma (GINA) guideline-defined classification levels of asthma control. The ACT is a validated, 5-item, patient-completed measure of asthma control with a recall period of four weeks.
Methods:
Cross-sectional survey comparing ACT score and GINA classification of asthma control among 2949 patients attending primary care physicians and specialists in France, Germany, Italy, Spain, the UK, and the USA.
Results:
The area under the receiver operating characteristics curve for ACT score predicting GINA control was 0.84 (95% CI 0.82–0.85). An ACT score of ≤19 (not well-controlled asthma) correctly predicted GINA-defined partly controlled/uncontrolled asthma 94% of the time, while an ACT score of ≥20 predicted GINA-defined controlled asthma 51% of the time, with kappa statistic of 0.42, representing moderate agreement.
Conclusions:
An ACT score ≤19 is useful for identifying patients with poorly controlled asthma as defined by GINA.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Elizabeth V Hillyer has received freelance writing assignments from Merck and Aerocrine. She has no shares in any pharmaceutical company. Professor David Price has consultant arrangements with: Altana, Boehringer-Ingelheim, GlaxoSmithKline, Ivax and Pfizer. He or his team have received grants and research support for research in respiratory disease from the following organisations: UK National Health Service, Altana Pharma, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Ivax, Merck Sharpe and Dohme, Novartis, Pfizer, and Schering Plough. Professor Price has also spoken for: Altana Pharma, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme and Pfizer. Angela E. Williams and Jacqueline R Carranza Rosenzweig are employees of GlaxoSmithKline.
Rights and permissions
About this article
Cite this article
Thomas, M., Kay, S., Pike, J. et al. The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 18, 41–49 (2009). https://doi.org/10.4104/pcrj.2009.00010
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4104/pcrj.2009.00010
This article is cited by
-
Designing and validating an experimental protocol to induce airway narrowing in older adults with and without asthma
BioMedical Engineering OnLine (2024)
-
Psychological distress and associated factors among asthmatic patients in Southern, Ethiopia, 2021
Asthma Research and Practice (2023)
-
Asthma control among treated US asthma patients in Practice Fusion’s electronic medical record research database
npj Primary Care Respiratory Medicine (2023)
-
Acute severe asthma in emergency department: clinical characteristics, risk factors, and predictors for poor outcome
The Egyptian Journal of Bronchology (2022)
-
Shifts in Asthma Evaluation and Management During COVID-19
Current Treatment Options in Allergy (2022)